In the last three months, 6 analysts have published ratings on Pacira BioSciences (NASDAQ:PCRX), offering a diverse range of perspectives from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $25.67, a high estimate of $39.00, and a low estimate of $16.00. Marking an increase of 6.21%, the current average surpasses the previous average price target of $24.17.

Exploring Analyst Ratings: An In-Depth Overview

A clear picture of Pacira BioSciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pacira BioSciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Pacira BioSciences analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Pacira BioSciences Better

Unraveling the Financial Story of Pacira BioSciences

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Over the 3 months period, Pacira BioSciences showcased positive performance, achieving a revenue growth rate of 2.83% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -85.11%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Pacira BioSciences's ROE excels beyond industry benchmarks, reaching -17.62%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Pacira BioSciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.06%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

The Significance of Analyst Ratings Explained

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.